FDA Drug Recalls

Recalls / Class II

Class IID-0492-2023

Product

Doxazosin 2 mg tablets, packaged in a) 30-count (NDC 70518-1560-00) and b) 90-count bottles (NDC 70518-1560-01), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

Affected lot / code info
Lot #: a) J0665197-120522, Exp. Date 12/31/2023; J0642497-082722, Exp. Date 09/30/2023 J0638552-080922, Exp. Date 08/31/2023. Lot #: b) B1808799-081622, Exp. Date 05/31/2024

Why it was recalled

cGMP Deviations

Recalling firm

Firm
RemedyRepack Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
625 Kolter Dr Ste 4, Indiana, Pennsylvania 15701-3571

Distribution

Quantity
a) 58 bottles, b) 6 bottles
Distribution pattern
RemedyRepack distributed product to consignees nationwide within the United States

Timeline

Recall initiated
2023-03-20
FDA classified
2023-03-31
Posted by FDA
2023-04-12
Terminated
2023-10-19
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0492-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls